Uwe Pelzer

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. doi request reprint Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
    Uwe Pelzer
    Uwe Pelzer, Jens M Stieler, Marianne Sinn, Timm Denecke, Sven Bischoff, Bernd Dörken, and Hanno Riess, Charité Universitätsmedizin Berlin Peter C Reitzig, Hospital Sana Klinikum Lichtenberg, Berlin Bernhard Opitz, Hospital St Elisabeth St Barbara, Halle Gerd Deutschinoff, Allgemeins Krankenhaus, Hagen Martina Stauch, Clinical Center, Kronach Sabine Hahnfeld, Clinical Center, Jena Lothar Müller, Clinical Center, Leer Martina Grunewald, Hospital Aschersleben, Aschersleben and Helmut Oettle, Clinical Center, Friedrichshafen, Germany
    J Clin Oncol 33:2028-34. 2015
  2. pmc Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy
    Uwe Pelzer
    Department of Hematology Oncology, Comprehensive Cancer Center, Universitatsmedizin Berlin Charite, Berlin, Germany
    Front Oncol 3:155. 2013
  3. pmc Blood group determinates incidence for pancreatic cancer in Germany
    U Pelzer
    Department of Hematology Oncology, Comprehensive Cancer Center, Charité Universitätsmedizin Berlin Berlin, Germany
    Front Physiol 4:118. 2013
  4. pmc Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial
    Uwe Pelzer
    Department of Hematology Oncology, CharitéCentrum fur Tumormedizin, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, Berlin 13353, Germany
    BMC Cancer 14:204. 2014
  5. doi request reprint [Multimodal treatment of pancreatic cancer]
    U Pelzer
    Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland
    Internist (Berl) 55:31-6. 2014
  6. doi request reprint First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
    Uwe Pelzer
    Charité Centrum für Tumormedizin, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 68:1173-8. 2011
  7. pmc Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
  8. doi request reprint Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
  9. pmc Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
  10. doi request reprint Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
    Uwe Pelzer
    Uwe Pelzer, Jens M Stieler, Marianne Sinn, Timm Denecke, Sven Bischoff, Bernd Dörken, and Hanno Riess, Charité Universitätsmedizin Berlin Peter C Reitzig, Hospital Sana Klinikum Lichtenberg, Berlin Bernhard Opitz, Hospital St Elisabeth St Barbara, Halle Gerd Deutschinoff, Allgemeins Krankenhaus, Hagen Martina Stauch, Clinical Center, Kronach Sabine Hahnfeld, Clinical Center, Jena Lothar Müller, Clinical Center, Leer Martina Grunewald, Hospital Aschersleben, Aschersleben and Helmut Oettle, Clinical Center, Friedrichshafen, Germany
    J Clin Oncol 33:2028-34. 2015
    ..Enoxaparin, a low-molecular weight heparin, is effective in prevention and treatment of VTEs. Some small studies have indicated that this benefit might extend to patients with cancer...
  2. pmc Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy
    Uwe Pelzer
    Department of Hematology Oncology, Comprehensive Cancer Center, Universitatsmedizin Berlin Charite, Berlin, Germany
    Front Oncol 3:155. 2013
    ....
  3. pmc Blood group determinates incidence for pancreatic cancer in Germany
    U Pelzer
    Department of Hematology Oncology, Comprehensive Cancer Center, Charité Universitätsmedizin Berlin Berlin, Germany
    Front Physiol 4:118. 2013
    ..001) whereas blood group 0 was less frequent in patients with PC (p < 0.001). Thus, our findings support the results from other non-German surveys. The causal trigger points of this carcinogenesis correlation are still not known...
  4. pmc Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial
    Uwe Pelzer
    Department of Hematology Oncology, CharitéCentrum fur Tumormedizin, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, Berlin 13353, Germany
    BMC Cancer 14:204. 2014
    ..We initiated this safety investigation to get feasibility information on intensified chemotherapy combined with LMWH in outpatients with APC treated in 1st line...
  5. doi request reprint [Multimodal treatment of pancreatic cancer]
    U Pelzer
    Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland
    Internist (Berl) 55:31-6. 2014
    ..Despite progress in the understanding of cancer biology and new treatment options, non-resectable adenocarcinoma of the pancreas remains a disease with a very poor prognosis...
  6. doi request reprint First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
    Uwe Pelzer
    Charité Centrum für Tumormedizin, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 68:1173-8. 2011
    ..The study is based on our completed dose finding phase I trial...
  7. pmc Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
    ..The positive influence of BIA determinate predictors by additional nutrition is currently under discussion...
  8. doi request reprint Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
    ....
  9. pmc Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
    ..This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy...
  10. doi request reprint Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011
    ..We initiated a phase III multicentre study comparing OFF versus best supportive care (BSC) in patients with APC progressing while on gemcitabine therapy...
  11. doi request reprint Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany
    Marianne Sinn
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite Universitatsmedizin Berlin, Germany
    Onkologie 35:755-60. 2012
    ..The results of Valle et al. in 2009 provided, for the first time, an evidence-based palliative treatment for this rare tumor type. So far no data are available in Germany regarding the current daily care practice...
  12. doi request reprint Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study
    Marianne Sinn
    Department of Medical Oncology and Haematology, Charite Universitatsmedizin Berlin, Germany
    J Surg Oncol 108:398-402. 2013
    ..The CONKO-001 study, which established gemcitabine after resection as adjuvant therapy, may provide data to answer this question...
  13. doi request reprint Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial
    Helmut Oettle
    Helmut Oettle, Hanno Riess, Jens M Stieler, Sven Bischoff, Marianne Sinn, Bernd Dörken, and Uwe Pelzer, Charitě Universitätsmedizin Ingo Schwaner, Clinical Center, Berlin Helmut Oettle, Clinical Center, Friedrichschafen Gerhard Heil, Clinical Center, Lüdenscheid Jörg Seraphin, Clinical Center, Northeim Martin Görner, Clinical Center, Bielefeld Matthias Mölle, Clinical Center, Dresden Tim F Greten, Hannover Medical School, Hannover and Volker Lakner, Clinical Center, Rostock, Germany
    J Clin Oncol 32:2423-9. 2014
    ..To assess the efficacy of a second-line regimen of oxaliplatin and folinic acid-modulated fluorouracil in patients with advanced pancreatic cancer who have experienced progression while receiving gemcitabine monotherapy...
  14. doi request reprint Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer
    Fritz Klein
    Department of General, Visceral, and Transplantation Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Surg Oncol 112:66-71. 2015
    ..In this study the prognostic relevance of DNA Index and classical histopathological parameters with regard to disease-free (DFS) and overall survival (OS) was analyzed within the CONKO-001 patient population...
  15. ncbi request reprint Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI
    Juri Ruf
    Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Berlin, Germany
    Pancreatology 5:266-72. 2005
    ..To determine the value of fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the detection of recurrent pancreatic cancer in comparison to computed tomography (CT) and magnetic resonance imaging (MRI)...